Transposagen differentiates itself from competitors on three key levels: unique gene editing technology, strong intellectual property and advanced technicalcapabilities. These advantages can be yours as well through all-in-one licensing and service partnerships with Transposagen.
Partner with us for leading cell engineering capabilities utilizing the most advancedgene editing technologies. Cell Line services available include stem cells, transformed cell lines and primary cells. Through strategic alliances, we can provide beginning-to-end solutions for pluripotent cell engineering, starting with iPS patient specific samples to differentiated cells.
We provide exclusivity for model creation through our portfolio of patents covering genetically engineered rat models with a broad range of valuable disease model phenotypes including: oncology, autoimmune or inflammatory diseases, severe combined immune deficiency (SCID), diabetes, obesity, susceptibility to pain, and phenotypes that are the result of mutations in drug transporter or drug metabolism genes.
Transposagen has partnered with the stem cell company, Stemgent, in order to provide beginning-to-end iPS cell gene editing services for reporter lines, isogenic and disease models. Learn more about our services with off-the-shelf iPS cells as well as patient specific cells for drug discovery.
Welcome to Transposagen, home of the industry’s most versatile collection of technologies and services for genetic engineering. Our technology portfolio includes XTN™TALEN site-specific nucleases for knockouts and knock-ins, the piggyBac™ transposon system for transgenesis and for translational research the only Footprint-Free™ gene editing vectors and service in the world.